Shares in Unitree Robotics opened 629 per cent above their issue price on Shanghai's STAR Market on Wednesday, briefly valuing the Hangzhou-based robot maker at close to $66bn before the gain eased back through the session. By the close the stock stood 460 per cent higher, leaving the company worth roughly $50bn, a figure that put it on a par with established Chinese technology manufacturers and comfortably ahead of the average first-day pop of 279 per cent recorded by mainland listings so far this year. It was the first debut of its kind on a mainland exchange, marking the arrival of a publicly traded humanoid robot maker at a moment when Chinese investors are hunting for the next beneficiary of the country's artificial intelligence push. The rally unfolded even as China's benchmark index fell on the day, underlining how narrowly the enthusiasm was targeted at Unitree rather than the wider market.

The mechanics of the listing help explain the scale of the reaction. Unitree priced its initial public offering at 150.80 yuan a share, issuing just over 40 million new shares to raise about 6.1bn yuan, roughly $905m, equivalent to a tenth of its enlarged capital. Demand from retail investors was extraordinary even by the standards of China's IPO market, with the online tranche oversubscribed by more than five thousand times and individual accounts submitting orders worth several trillion yuan against a tiny pool of available stock. Backers including the artificial intelligence group DeepSeek and the technology conglomerate Tencent joined the offering alongside state-linked institutional investors, a combination that lent the listing both retail excitement and a degree of political endorsement. Founder Wang Xingxing, who retains around a fifth of the company, saw his paper wealth climb into double-digit billions within hours of trading beginning.

Unitree's product range spans four-legged robots built for industrial and research use and humanoid machines capable of running, dancing and performing martial arts sequences that have become familiar through viral demonstration videos, including an appearance on China's state television Spring Festival broadcast. The company shipped more than five thousand humanoid units last year, more than any other manufacturer globally, alongside cumulative sales exceeding thirty thousand of its four-legged robots since 2023. Its 2025 revenue reached 1.7bn yuan, more than four times the previous year's figure, with net profit of 278m yuan and gross margins above 60 per cent, a rare combination of scale and profitability in a sector still dominated by cash-burning rivals.

That profitability has not silenced scepticism. Unitree's valuation implies a price to sales ratio of nearly 36, against roughly 20 for Hong Kong-listed peers UBTech Robotics and Shenzhen Dobot, and analysts including Vey-Sern Ling at Union Bancaire Privée have argued the surge reflects retail speculation rather than any change in the company's fundamentals. Much of Unitree's hardware remains sold to universities and research institutions rather than deployed in revenue-generating commercial settings, and the gap between demonstration and durable industrial use persists across the humanoid robotics field. First-quarter figures released before the listing showed adjusted profit falling by more than half year on year as spending on research and sales increased, a reminder that the path to sustained earnings is far from settled.

Beijing's backing looms over the entire sector. Embodied artificial intelligence has become one of the government's designated strategic technologies, sitting alongside semiconductors in state industrial policy, and Unitree's listing arrives as rivals including AgiBot and Leju Robotics prepare their own share sales. A recent American move to restrict imports of foreign-made humanoid and four-legged robots adds a complicating layer, given the United States accounted for around 13 per cent of Unitree's revenue last year, though existing models already in the market are expected to remain unaffected. Whether Wednesday's debut proves a durable marker of value or the peak of a speculative wave will depend on how quickly commercial deployment catches up with the valuations now being placed on the sector.

For Britain, the episode is a reminder of how far state-backed capital can move ahead of proven commercial use, a dynamic with direct relevance to the UK's own life sciences and health technology ambitions. NHS trusts and social care providers are increasingly courted by robotics and automation vendors promising relief for workforce shortages, from surgical assistance to logistics and elderly care support, yet procurement decisions in Britain are governed by far tighter evidential and safety thresholds than a Shanghai retail investor applies to a share subscription. Ministers weighing life sciences investment strategy, and NHS leaders assessing automation pilots, would do well to treat Unitree's valuation as a signal of where global capital is flowing rather than as evidence that the underlying technology is ready for the wards.